Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Certara2019 年 5 月 2 日
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Certara2019 年 4 月 22 日
Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics Poster Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics Certara2019 年 4 月 22 日
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Certara2019 年 4 月 22 日
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Certara2019 年 4 月 22 日
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Certara2019 年 4 月 22 日
Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin Poster Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin Certara2018 年 11 月 4 日
Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy Poster Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy Certara2018 年 10 月 8 日
Precision Dosing in Clinical Medicine: Present and Future Publication Precision Dosing in Clinical Medicine: Present and Future Certara2018 年 7 月 20 日
Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data Publication Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data Certara2018 年 6 月 22 日
